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Abstract 
Mechanistic target of rapamycin complex 1 (mTORC1) at lysosomes plays a pivotal role in 
cell growth control where an array of large multi-protein complexes relay nutrient, energy 
and growth signal inputs through mTORC1. In cancer cells, such regulation often becomes 
disconnected, leading to uncontrolled cell growth and an elevation of cellular stress. 
Consequently, cancer cells often loose homeostatic balance as they grow in unfavorable 
conditions, i.e., when nutrients and energy are limiting yet mTORC1 is still aberrantly 
activated. Cancer cells loose signaling flexibility because of hyperactive mTORC1 that leads 
to heightened cellular stress and loss of nutrient and energy homeostasis, all of which are 
potential avenues for cancer therapy. Cancer cells can take advantage of mTORC1 to drive 
cell growth and proliferation while also maintaining cancer cell survival. Autophagy 
regulation by mTORC1 is critically involved in nutrient and energy homeostasis, cell growth 
control and survival. Targeting mTORC1 and autophagy as a potential strategy to treat 
cancer has grown in interest over the last few decades. This review will explore the signaling 
pathways central to mTORC1 and autophagy regulation, and cancer vulnerabilities when 
considering anti-cancer therapies. 
 
 
Introduction 
Mechanistic target of rapamycin complex 1 (mTORC1) senses and integrates a variety of 
inputs, including growth signals, amino acid levels and energy status and then orchestrates 
cell growth control in a multifaceted manner. For a cell to rapidly proliferate it needs to 
build-up its biomass before the cell can effectively divide. Cellular components are doubled 
and include not only protein signaling complexes, receptors, transporters and enzymes but 
also cellular scaffold proteins that permit the cytoskeleton to expand as the cell steadily 
grows. To rapidly increase cellular biomass, mTORC1 promotes ribosomal biogenesis to 
enhance the cell’s protein translation machinery (reviewed in [1]). Consequently, the 
capacity of the cell to manufacture de novo protein is greatly augmented by mTORC1 and is 
essential for rapidly proliferating cells. Generation of de novo protein can be considered a 
rate limiting factor for cells that are either in the G1 or G2 growth phase of the cell cycle. 
Given the large quantity of amino acids and ATP that is consumed as a cell produces protein, 
tight regulation ensures that mTORC1 is only active when there is a sufficient supply of 
nutrients and energy. It is not surprising that mTORC1 is often aberrantly activated in 
cancer. As well as enhancing tumor growth and proliferative rate, mTORC1 is involved in 
metabolic transformation, neovascularisation and metastasis. mTORC1 contributes to tumor 
growth through the regulation of protein translation, hypoxia signaling, autophagy and 
synthetic anabolic pathways in the pentose phosphate pathway that builds tumor mass 
while maintaining energy and nutrient homeostasis (reviewed in [2]). mTORC1 activation 
correlates with metastasis, poor patient survival and resistance to anticancer agents [3]. 
 
mTORC1 hyper-activation through genetic mutations of upstream components occurs in 
sporadic cancer but also underlies several tumor predisposition syndromes, such as 
tuberous sclerosis complex (TSC) [4] and Cowden disease/PTEN hamartoma syndrome [5]. A 
lot of our current understanding of mTORC1 signal transduction and cell growth control has 
been gained through research on such rare genetic disorders. TSC is an autosomal dominant 
condition caused through mutations in either TSC1 or TSC2 and is characterized by tumor 
growth in multiple organs, neurocognitive problems and epilepsy [4]. The TSC1 and TSC2 
proteins form a functional tumor suppressor complex which has GTPase-activating protein 
(GAP) activity towards Ras homologue enriched in brain (Rheb). Rheb loaded with GTP 
potently activates mTORC1, while hydrolysis of GTP through interaction with TSC1/TSC2 
converts Rheb to an inactive GDP-bound state and switches mTORC1 off [6,7]. 
Consequently, loss-of-function mutations in either TSC1 or TSC2 cause aberrant signal 
transduction through mTORC1. TSC1 and TSC2 are mutated in approximately 15% of bladder 
cancer and 3% of clear cell renal carcinomas. TSC2 is mutated in 3% of bladder cancers and 
in 8% of well-differentiated pancreatic neuroendocrine tumors [8-10]. Whereas, activating 
mutations within the mTOR kinase domain have been identified in multiple cancer subtypes, 
with the highest number in kidney, colorectal, endometrial, and lung cancers [11]. 
Mutations within TSC1, TSC2 and mTOR are uncommon in sporadic cancer, while mutations 
within genes that function upstream of mTOR are much more common, i.e., within PTEN or 
RAS. Additionally, gene amplification of growth factor receptors that activate these 
pathways, such as epidermal growth factor receptors and platelet-derived growth factor 
receptors are examples that result in increased mTORC1 signaling. Frequent mutations that 
affect the wider PI3K/PTEN/Akt-TSC1/TSC2-Rheb/mTORC1 signaling network have also been 
reported in renal cancers and head and neck cancer [12,13]. The signaling pathway is 
illustrated in Figure 1. 
 
mTOR signal transduction 
 
mTOR is a serine/threonine protein kinase that is integral to mTORC1. mTORC1 consists of 
the core components; mTOR, rapamycin-associated protein of TOR (Raptor) and mLST8. In 
addition, proline-rich Akt substrate of 40 kDa (PRAS40) [14] and DEP domain containing 
mTOR-interacting protein (DEPTOR) can also associate with and negatively regulate 
mTORC1 [15]. mTOR and mLST8 are also integral to a second complex called mTORC2. 
Components distinctive to mTORC2 include rapamycin insensitive companion of TOR 
(Rictor), mSIN1 and Protor [16]. mTORC1 is the better studied of the two complexes 
involved in managing multiple biosynthetic pathways and plays a key anabolic role in 
promoting cell growth and proliferation. As well as promoting cell growth and proliferation, 
mTORC2 influences cell morphology through cytoskeletal organization. mTORC2 can also 
indirectly promote mTORC1 activation via activation of Akt. mTORC2 directly 
phosphorylates Akt on Ser473, which enhances Akt activity when additionally 
phosphorylated at Ser308 by PDK1 within the PI3K signaling pathway [17]. Activation of Akt 
then promotes signal transduction through mTORC1 via switching off the TSC1/TSC2 tumor 
suppressor complex. Consequently, mTORC2 could be considered to function upstream of 
mTORC1. 
 
When complexed with TSC1, TSC2 functions as a GAP towards a small G-protein called Rheb, 
reverting Rheb to an inactive GDP-bound form. Reversion of Rheb to an inactive GDP-bound 
form turns mTORC1 off [6,7]. Rheb becomes activated when the TSC1/TSC2 complex is 
repressed through an array of upstream kinases within mitogenic and hormone induced 
pathways (depicted in Figure 1). PI3K/AKT and Ras/MAPK/ERK/RSK cell signaling pathways 
regulate mTORC1 signaling via TSC1/TSC2. Both AKT (also referred to as PKB) [18] and RSK 
[19] can phosphorylate TSC2 on over-lapping and distinct residues that lead to inactivation 
of TSC1/TSC2. As well as growth signaling inputs, mTORC1 is also regulated by energy and 
this occurs through the energy sensing AMP-dependent protein kinase (AMPK). AMPK 
becomes active in response to energy stress, when cellular ATP levels decline and AMP 
levels sequentially increase. AMPK phosphorylates TSC2 on Thr1227 and Ser1345, which 
enhances the function of TSC1/TSC2 to act as a RhebGAP [20]. AMPK is itself activated by 
the serine/threonine kinase LKB1/STK11 [19] or the Ca2+/CaM-dependent protein kinase 
kinase β (CaMKKβ) [21] that phosphorylates the α-subunit of AMPK on Thr172. AMPK-
dependent phosphorylation of TSC2 on Thr1227 and Ser1345 [22] is lost when inactivating 
mutations within LKB1 occur, giving rise to Peutz-Jeghers Syndrome that predisposes 
patients to hamartomatous polyps in the gastrointestinal tract and development of cancer 
[23]. 
 mTORC1 can only be activated when nutrients are present. There are multiple mechanisms 
of nutrient sensing involving mTORC1 and lysosomes. Initially, Sancak et al. [24] and Kim et 
al. [25] identified the Rag small G-proteins as important mediators of amino acid signaling. 
Four Rag GTPases were identified as Raptor interacting proteins. The active complex 
consists of either RagA-GTP or RagB-GTP associated with either RagC-GDP or RagD-GDP as a 
heterodimer [24]. During conditions when amino acids are sufficient, RagA and RagB switch 
to an active GTP-bound state causing Raptor association. The Rag heterodimer then 
translocates mTORC1 to the ‘Ragulator complex’ [26] that is closely associated with v-
ATPase on lysosomal membranes [27] (Figure 2). Immunofluorescence studies revealed that 
mTORC1 localized to lysosomes either in the presence of amino acids or when active Rag 
heterodimers were expressed [24]. It should be noted that Rheb is also lysosomally localized 
via C-terminal prenylation and the association of mTORC1 with Rheb on lysosomal 
membranes is required for its activity [28]. Therefore, under conditions of nutrient 
withdrawal, mTORC1 is cytoplasmically localized in an inactive state as it cannot interact 
with lysosomal-tethered Rheb. When nutrients become plentiful, the Rag proteins and 
mTORC1 are actively translocated to the Ragulator complex on the membrane surface of 
lysosomes, where Rheb-GTP is then required for mTORC1 activation.  
 
The Ragulator complex consists of five proteins (MP1, p14, p18, HBXIP and C7ORF59), which 
are referred to as the late endosomal/lysosomal adaptor, MAPK and mTOR activator 1-5 
(LAMTOR1-5) [26]. The Ragulator complex functions as a guanine nucleotide exchange 
factor (GEF) towards the RagA and RagB small G proteins to convert them to an active GTP-
bound state [29]. At lysosomes, the tumor suppressor protein Folliculin (FLCN) also 
positively regulates these Rag heterodimers by acting as a GAP towards RagC and RagD 
[30,31]. For instance, these two positive signaling inputs switch these Rag heterodimers to 
an active state, where RagA/B becomes GTP-bound and RagC/D becomes GDP-bound. These 
Rag heterodimers are also regulated by RagGTPases and GTRs-1 (GATOR) and GATOR2, and 
like the Ragulator complex are lysosomal localized and function as a multi-protein complex 
[32]. As a negative regulator of mTORC1, GATOR1 acts as a GAP towards RagA and RagB to 
switch them to an inactive state, preventing Rag-mediated translocation of mTORC1 to the 
lysosome. A recently identified protein complex called KICSTOR was found to be necessary 
for tethering GATOR1 to the lysosome [33,34]. GATOR2 lies upstream of GATOR1 and 
functions as a negative regulator of GATOR1. GATOR2 is positively regulated by nutrients. 
The branched chained amino acid, leucine, is sensed via three Sestrins (SESN1− SESN3), 
leading to activation of GATOR2. Sestrins are thought to be the main leucine sensor that 
activates mTORC1. Activation of GATOR2 then sequentially inactivates GATOR1, switching 
the Rag heterodimers to an active conformation to translocate mTORC1 to lysosomes to 
promote mTORC1 [35-36]. 
 
Lysosomal recruitment of mTORC1 by the Rag GTPase also allows mTORC1 to directly 
interface with AMPK and ULK1 (unc-51 like autophagy activating kinase 1). Energy and 
nutrients are replenished within the lysosome through catabolism, where these amino acids 
are thought to be actively sensed within the lumen of the lysosome and are dependent on 
the vacuolar H+-ATPase (v-ATPase). The v-ATPase monitors the amino acid levels within the 
lysosome and relays this signal to the Ragulator complex on the outside, termed the ‘inside-
out signal’ [27]. The amino acid signal to the v-ATPase is likely relayed via amino acid 
transporters that reside on the lysosomal membrane. Amino acids are transported out of 
the lysosome by amino acid transporters that include PAT1 (proton-assisted amino acid 
transporter) and SLC38A9. SLC38A9 was shown to interact with the Rag-Ragulator-v-ATPase 
complex on lysosomes and is required for arginine-mediated activation of mTORC1 [37-39]. 
The v-ATPase is also critically involved in sensing the energy status of the cell. Under 
conditions of glucose starvation, axis inhibition protein (AXIN) is recruited to the v-ATPase 
on lysosomal membranes [40]. When cells are energy starved, AXIN functions as a scaffold 
to recruit LKB1-AMPK to lysosomes, where this AXIN-LKB1-AMPK complex binds to 
LAMTOR1 as part of the Ragulator complex. Importantly, LAMTOR1 dramatically reduces 
the concentration of AMP that is required to promote association of AXIN-LKB1 with AMPK, 
which is necessary for AMPK activation. The presence of LAMTOR1 lowers the AMP 
concentration to 5 µM that is required for AMPK activation at lysosomes, while much higher 
AMP concentrations (>150 µM) are required when LAMTOR1 is absent. Therefore, 
recruitment of AMPK by AXIN to the Ragulator complex is regulated during energy 
starvation involving the v-ATPase and switches mTORC1 off [40]. 
 
The lysosome not only acts as a signaling hub to relay the nutrient and energy status of the 
cell to mTORC1, lysosomes also relay the signaling inputs from growth factor receptors on 
the plasma membrane. To efficiently interface with the outside signals via growth factor 
receptors, the localization of lysosomes is dynamically regulated. Lysosomes are 
translocated in the direction of the plasma membrane when nutrients and energy are in 
sufficient supply [41]. Proximal localization of lysosomal-tethered mTORC1 and Rheb to the 
plasma membrane ensures for rapid signal transduction via growth factor receptors to 
TSC1/TSC2 and sequential Rheb/mTORC1 activation. Conversely, lysosomal activity is down-
regulated when proximal to the plasma membrane to minimize catabolism while cells 
actively grow. When nutrients become limiting, lysosomes are translocated inwards towards 
the nuclear periphery where autophagosomal flux and lysosomal activity is enhanced. Such 
a mechanism to partition mTORC1 away from plasma membrane localized growth factor 
receptors leads to rapid mTORC1 inhibition. To further deactivate mTORC1 under nutrient 
deprivation, mTORC1 is displaced from the lysosomal surface, away from Rheb. 
 
Nutrients are sensed by many signaling inputs. A recent finding revealed that when arginine 
levels are low, TSC1/2 associates with Rheb, leading to reversion of Rheb to an inactive GDP-
bound state [42]. In this study, it was found that arginine was sufficient to prevent the 
RhebGAP function of TSC1/TSC2, which indicates an additional signaling mechanism that is 
dependent on arginine. Recent work also showed that Cytosolic Arginine Sensor for 
MTORC1 (CASTOR) subunit 1 interacts with GATOR2 when cells are deprived of arginine and 
leads to mTORC1 inhibition. When arginine is resupplied, arginine binds to CASTOR1 and 
disrupts the inhibited CASTOR1-GATOR2 complex that then allows GATOR2 to turn off 
GATOR1 to sequentially activate mTORC1 [43]. Collectively, mTORC1 signaling is highly 
complex with multiple inputs from nutrients, energy and receptor-mediated growth signals 
that ensures that the growth status of the cell is efficiently managed. 
 
Autophagy regulation by mTORC1 and nutrient and energy homeostasis 
 
While the mTORC1 signaling nexus is lysosomal localized, the main function of lysosomes is 
to conduct autophagy. Autophagy is a catabolic process whereby damaged or unwanted 
organelles and macromolecules are degraded via sequestration in membrane-bound 
autophagosomes that fuse with lysosomes to allow enzymatic break down of its contents. 
Autophagy recycles components through catabolic degradation to generate energy and 
components for biosynthetic reactions [44].  ‘Self-eating’ was first observed in 1963 by 
Christian de Duve [45], whose subsequent research led to the detection of both macro- and 
microautophagy [46]. Chaperone-mediated autophagy was discovered much later in 1981 
[47]. Microautophagy is concerned with maintenance of organelle size, membrane 
homeostasis and survival. It is triggered in conditions of nitrogen starvation (but also when 
mTORC1 is inhibited). In microautophagy, lysosomes directly engulf malfunctioning or 
damaged organelles [48]. Chaperone-mediated autophagy uses a translocation protein 
complex to deliver single, soluble proteins to the lysosome where they must be unfolded 
before entry. With chaperone-mediated autophagy, the high degree of selectivity may help 
to prevent degradation of essential structures whilst still acquiring amino acids [47]. 
Ultimately, all forms of autophagy shuttle macromolecules into lysosomes for digestion and 
recycling of components. During macroautophagy the cytoplasm, proteins and organelles 
are internalized within double-membrane vesicles termed autophagosomes. In this review, 
we will now refer to macroautophagy as autophagy. 
 
Autophagy is activated within the first few hours of starvation, increasing in activity until up 
to about 6 hours before slowly declining [49]. Autophagy is tightly regulated by the kinase 
ULK1 as an active complex with autophagy-related (ATG)-13, focal adhesion kinase family 
interacting protein of 200 kDa (FIP200) and ATG101. This protein kinase complex with ULK1 
is essential for autophagy, as loss of ULK1, ATG13 or ATG101 expression impairs autophagy 
[50-53]. Nutrient withdrawal stimulates ULK1 complex activation via ULK1 
autophosphorylation and phosphorylation of the ATG13 and FIP200 binding partners [51], 
which leads to relocalization of this protein complex to autophagic isolation membranes to 
initiate autophagy [54].  
 
To coordinate the growth status of the cell depending on the availability of nutrients and 
energy, mTORC1 relies on the signaling input of ULK1 to help regenerate energy and amino 
acids from the cells. Furthermore, there is signaling interplay from AMPK, the energy 
sensing kinase that is turned on when energy supply becomes limited. Homeostatic balance 
is tightly maintained by this mTORC1-AMPK-ULK1 kinase triad. The activities of mTORC1, 
AMPK and ULK1 are tightly regulated on lysosomal membranes. Over the last two decades, 
research has delineated a complex web of signaling mechanisms that regulates the kinase 
activities of mTORC1, AMPK and ULK1, which essentially coordinate cell growth, energy 
status, and cell regeneration, respectively. A normal cell can efficiently switch between 
growth and growth arrested states, which is necessary for cells to maintain energy and 
amino acid homeostasis (Figure 3). In a growth arrested state, when energy or nutrients 
become limiting, cells employ a series of negative feedback mechanisms from AMPK and 
ULK1 that rapidly switch off mTORC1 and potently induce autophagy. The cell will then 
regenerate their amino acid and energy levels, leading to AMPK and ULK1 inactivation and 
allowing mTORC1 to be switched on again to promote cell growth. During the growth phase, 
mTORC1 potently down-regulates autophagy and ensures that a steady anabolic rate of 
growth is maintained. mTORC1 phosphorylates ULK1, which slows down autophagosomal 
maturation and lysosomal activity [51,53]. However, it should be noted that even when 
mTORC1 is active, a basal level of lysosomal activity is still present to maintain a constant 
low level of protein degradation. Cancer cells with constitutive mTORC1 activation have less 
signaling flexibility to relay the appropriate signaling input from AMPK and ULK1 depending 
on energy and nutrient supply. Such dysregulated signaling can lead to metabolic 
transformation. 
 
As another mechanism of regulation within this kinase triad, AMPK indirectly inactivates 
mTORC1 via ULK1. AMPK phosphorylates ULK1, which is necessary for ULK1 stabilization 
and its full activity [55-59]. ULK1 then sequentially phosphorylates Raptor, which prevents 
Raptor associating with mTORC1 substrates [60]. Raptor is considered a scaffold protein of 
mTORC1 that is necessary for recruiting and delivering substrates to the kinase active site of 
mTORC1. As ULK1-phosphorylated Raptor can no longer bind substrates and present them 
to the mTOR kinase, mTORC1 signaling is dramatically down-regulated. AMPK also 
phosphorylates Raptor and is thought to be inhibitory [61]. Therefore, both AMPK and ULK1 
work together to down-regulate mTORC1 when energy levels are low. 
 
There are additional signaling mechanisms that ensure that autophagy is tightly regulated. 
For instance, ULK1 was also found to directly inhibit AMPK by phosphorylation [62]. 
Presumably, this signaling feedback mechanism from ULK1 towards AMPK ensures that 
autophagy is not constitutively turned on for long periods of time and would allow mTORC1-
mediated signaling to become more dominant after the cell has recovered its levels of 
nutrients and energy. mTORC1 becomes the dominant kinase when nutrient supply is 
sufficient and this is because phosphorylation of ULK1 by mTORC1 blocks the ability of 
AMPK to phosphorylate and activate ULK1 [55,56]. Another mechanism by how mTORC1 
inhibits autophagy is via phosphorylation of Autophagy/Beclin-1 regulator 1 (AMBRA1). 
mTORC1 inhibits ULK1 indirectly through phosphorylation of AMBRA1 at Ser52 [63]. 
Phosphorylation of AMBRA1 by mTORC1 prevents Lys-63-linked ubiquitination of ULK1 by 
TNF receptor-associated factor 6, E3 ubiquitin protein ligase (TRAF6). Lys-63-linked 
ubiquitination of ULK1 by TRAF6 causes ULK1 to dimerize, leading to its enhanced stability 
and sequential activation. During conditions that favor mTORC1 activation, AMBRA1 is kept 
in an inactive state and is tethered to intracellular vesicles as part of a dynein motor 
complex. However, upon conditions when mTORC1 is inactivated, autophagy is rapidly 
promoted through Lys-63-ubiquitination of ULK1 by the AMBRA1-TRAF6 complex that leads 
to ULK1 stabilization. 
 
Longer-term regulation of autophagy by mTORC1 is managed by a set of transcription 
factors that are responsible for lysosomal biogenesis; transcription factor EB (TFEB) [64] and 
transcription factor binding to IGHM enhancer 3 (TFE3) [65]. These TFEB and TFE3 
transcription factors are retained to lysosomes via the active Rag heterodimers when 
nutrients are sufficient and mTORC1 phosphorylates TFEB at SerS142 [64] and TFE3 at 
Ser311 [65] to keep them inactive. When nutrients become limiting, TFEB and TFE3 are 
dephosphorylated and are then released, allowing them to translocate to the nucleus to 
drive gene-expression of lysosomal genes. 
 
Therapeutic avenues to treat cancer involving mTORC1, autophagy and endoplasmic 
reticulum stress 
 
While targeting autophagy has potential as an anti-cancer therapy, there are some current 
challenges. One issue is that not all cancer cells require autophagy for cell survival, so 
autophagy inhibitors are unlikely to be broadly effective. While autophagy can function as a 
key survival pathway in some cancer cells, restoration of autophagy in other cancer cells can 
instead enhance cell death [66]. At early stages of cancer progression, autophagy is often 
involved in cancer cell survival. However, at later stages of cancer progression, autophagy is 
often heavily compromised through genetic instability, causing loss of or mutation of 
autophagy genes. As an example, Beclin 1 (BECN1) was shown to be monoallelically deleted 
in 40-75% of sporadic human breast cancers and ovarian cancers [67].  
 
Autophagy can either promote or antagonize cancer development. Such variation in the 
dependency of autophagy makes it technically tricky when considering autophagy as a 
therapy for cancer (reviewed in detail [68]). If a tumor was initially screened for autophagy 
activity and dependence for survival, would stratifying cancer patients improve efficacy 
when considering autophagy as a therapeutic target? Patient stratification would certainly 
help, however, there is a current lack of molecular tools or biomarkers to robustly ascertain 
whether autophagy is either potentially activated or severely compromised in patient 
material. Immunohistochemistry of LC3 in patient tumor tissue is not particularly 
informative as it can be misleading. This is because an accumulation of LC3 (which indicates 
that there are more autophagosomes in the cell) could mean that autophagy is either 
enhanced or impaired. Indeed, enhanced autophagy could lead to an accumulation of LC3. 
Or conversely, LC3 accumulation could also mean that there is a build-up of 
autophagosomes due to an inhibition of autophagosomal flux. A robust method to 
determine autophagy within tumor tissue is clearly needed to accurately stratify patients. If 
patient stratification regarding dependency of autophagy for cancer cell survival was 
improved, targeting autophagy as a therapy would become much more viable a strategy. 
 
mTORC1 inhibitors have had much clinical interest for the treatment of cancer. The first-
generation inhibitors of mTORC1 are called rapalogues; rapamycin analogues with improved 
pharmacokinetics that bind allosterically and inhibit mTORC1 as a FKBP12-rapamycin 
protein-drug complex. In 2007, the rapalogue called temsirolimus (and later, everolimus) 
was approved for advanced-stage renal cell carcinoma and was the first mTORC1 inhibitor 
that was approved for cancer [69]. The median overall survival of patients with renal cell 
carcinoma treated with temsirolimius was 10.9 months. While with everolimus, survival was 
observed to be increased by 5.9 months in advanced renal cell carcinoma patients who 
previously failed with treatment with either of the receptor tyrosine kinase inhibitors, 
sorafenib or sunitinib [70]. Later, temsirolimus was approved for the treatment of mantle 
cell lymphoma [71]. Given the involvement of mTORC1 in cell growth control and cancer 
progression it is surprising that mTORC1 inhibitors have not been more successful in 
treating a wider range of cancers. However, there is still much clinical interest; there is over 
400 registered trials within clinicaltrials.gov using mTOR inhibitors (both rapalogues and the 
2nd generation ATP-competitive mTOR kinase inhibitors) as a mono agent or when 
combined with other drugs to treat many cancer types, including melanoma, myeloma, 
breast, renal, gynecological and brain cancers. 
 
One reason why rapalogues have had limited clinical use to treat cancer is that their drug 
action is cytostatic rather than cytotoxic, i.e., rapalogues arrest cancer cell growth instead of 
killing them. The cytostatic property of rapalogues is partly through the promotion of 
autophagy. However, it is important to note that mTORC1 signaling towards autophagy is 
partially rapamycin resistant and the level of resistance varies depending on cell-type. The 
variation in the ability of rapamycin to induce autophagy could be due to the stability of 
mTORC1. It was postulated that cells with a more unstable mTORC1 conformation would 
have heightened sensitivity to rapamycin, which would fully inhibit mTORC1 and induce 
autophagy [72]. In this study, it was found that rapamycin-resistant cells became sensitized 
to rapamycin when combined with a non-efficacious, low concentration of an ATP-
competitive mTOR inhibitor (i.e., at concentrations that is unable to inhibit mTORC1 or 
mTORC2 as a mono agent). It is therefore feasible that combination treatment of ATP-
competitive mTOR inhibitors with rapalogues would more completely block mTORC1 and 
restore autophagy in cancer cells where the autophagy pathway is compromised. ATP-
competitive mTOR inhibitors when used at higher concentrations to inhibit both mTORC1 
and mTORC2 would potently induce autophagy initially. However, after longer periods of 
mTORC2 inhibition the cytoskeleton would be reorganized and would lead to impaired 
autophagosomal flux. 
 
While directly targeting mTORC1 and autophagy has potential issues and caveats when 
considering them as an anticancer therapy, these pathways still have much potential for a 
targeted approach to selectively kill cancer cells. For instance, the imbalance to cell signaling 
at the level of the lysosome, i.e., mTOR, AMPK and ULK1, in many cancers often leaves the 
cancer cell with vulnerabilities that could be exploited. One critical cancer vulnerability is a 
lack of homeostatic flexibility within the mTOR, AMPK and ULK1 signaling pathways that is 
caused by constitutively high levels of mTORC1 signaling. Cancer cells with hyperactive 
mTORC1 are unable to efficiently restore homeostatic balance during periods of cell stress. 
For instance, a cancer cell will still maintain a high level of cell growth in the presence of cell 
stress, where these conflicting signals of cell growth and chronic stress will trigger cell 
death. In contrast, a non-cancer cell will become growth arrested under cell stress, which 
will allow these normal cells to better tolerate the stress input and effectively restore 
homeostatic balance.  
A good example of a stress pathway that is intrinsically linked to mTORC1 and 
autophagy and is necessary for maintaining cellular homeostasis is endoplasmic reticulum 
(ER) stress. One consequence of hyperactive mTORC1 and repression of autophagy is that 
ER stress becomes markedly elevated. This is because autophagy is normally utilized by a 
cell to remove unfolded protein aggregates in the ER to efficiently restore the protein 
folding environment [73]. To further help maintain protein turn-over via degradation while 
autophagy is down-regulated, mTORC1 upregulates the proteasome [74]. When autophagy 
is compromised, the proteasome becomes the primary proteolytic pathway to clear the cell 
of unfolded protein aggregates, thereby restoring ER homeostasis and preventing cell death 
[75]. Given this higher dependency on the proteasome to lessen the burden of ER stress, a 
potential therapeutic strategy to target mTORC1-driven cancer cells with down-regulated 
autophagy could be through proteasomal inhibition, with the aim to push the levels of ER 
stress beyond a tolerated survival threshold. In support of this therapeutic concept, 
selective cytotoxicity using proteasome inhibitors has been shown towards cancer cell lines 
with heightened signal transduction through mTORC1 [76-78]. Regarding anti-cancer 
therapy, proteasome inhibitors are currently being used in the clinic for the treatment of 
multiple myeloma, recurrent multiple myeloma and ma
 Concluding remarks 
 
Much progress has been made regarding the signaling interplay between mTORC1 and 
autophagy and how the nutrient and energy status of the cell is tightly regulated at the level 
of lysosomes. During the late stages of cancer, it is common that mTORC1 is upregulated 
and autophagy becomes heavily compromised, leading to an inflexibility in 
mTORC1/AMPK/ULK1 signaling to maintain homeostasis. While targeting autophagy has 
promise as an anti-cancer therapy, there is a real need to better stratify patients regarding 
the dependence of cancer cells to autophagy to make such therapies more effective. 
Targeting the vulnerabilities of mTORC1-hyperactive cancer cells through promoting stress 
pathways, such as ER stress, has the potential to impact a wider range of cancers when 
compared to the current mTORC1 inhibitors that are limited due to their cytostatic 
properties. Future work is needed to better understand how we can further exploit the 
signaling inflexibility that cancer cells when mTORC1 and autophagy signaling is 
dysregulated. Such research would allow for better targeted therapies and would improve 
patient survival.    
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Figure 1: mTORC1 signal transduction and tumor suppressors. Growth factor signal 
transduction via receptors on the plasma membrane switches off the TSC1/TSC2 tumor 
suppressor complex (where loss of function mutations causes Tuberous Sclerosis Complex). 
These include the Ras/Raf/MAPK/ERK/RSK and PI3K/AKT signaling pathways. Tumor 
suppressors upstream of TSC1/TSC2 include PTEN and LKB1, where mutations in these 
genes can cause Cowden’s syndrome and Peutz-Jeghers syndrome, respectively. Upon 
growth factor stimulation and inactivation of TSC1/TSC2, Rheb is converted to an active 
GTP-bound state that enhances mTORC1 activation and cell growth control. mTORC1 
activation also potently inhibits autophagy. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: mTORC1 signaling nexus at the lysosome. Amino acids within the lumen of the 
lysosome signal through to the Ragulator complex (coined as the ‘inside-out signal’). Amino 
acid transporters (such as PAT1 and SLC38A9) transport amino acids into the cytoplasm and 
are required for mTORC1 activation. Through the Ragulator complex, the Rag GTPase 
heterodimers are switched to an active state to recruit mTORC1 to the lysosome. As a 
mechanism to sense amino acids, arginine inhibits both TSC1/TSC2 and CASTOR, negative 
regulators of Rheb and GATOR2, respectively. Leucine positively switches on GATOR 2 via 
Sestrins. Dotted red inhibitory lines between Sestrins-Gator2, CASTOR-Gator2, and Gator1-
Rag are not inhibitory when nutrients (leucine and arginine) are present. Signal transduction 
via growth factors inactivates TSC1/TSC2 (the dotted red inhibitory line between TSC1/2 and 
Rheb is not inhibitory in the presence of a growth signal input), which converts Rheb to an 
active GTP-bound state to induce mTORC1 kinase activity. Under energy deprivation, 
LKB1/AMPK docks to the Ragulator complex through AXIN to switch off mTORC1. When 
energy is sufficient, the dotted red inhibitory line between AMPK and the regulator complex 
is not inhibitory. 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: The mTORC1-AMPK-ULK1 kinase triad. Signaling interplay and feedback 
mechanisms between mTORC1, AMPK and ULK1 is essential for energy and nutrient 
homeostasis. Under energy deprivation, AMPK activates ULK1 and switches off mTORC1 via 
phosphorylation of both TSC2 and Raptor to down-regulate cell growth. When nutrients and 
energy are in supply, mTORC1 becomes the dominant kinase, which turns off ULK1. 
However, under nutrient deprivation, ULK1 is gradually enhanced as mTORC1 becomes 
inactivated. Reduced phosphorylation of ULK1 by mTORC1 causes ULK1 stabilization and 
sequential activation to drive autophagy. ULK1 also directly phosphorylates Raptor to 
further turn off mTORC1. To restrict the duration of ULK1 activity and to prevent 
constitutive ULK1 activation, ULK1 phosphorylates and inactivates AMPK. Both inputs of 
AMPK activation (via energy starvation) and mTORC1 inhibition (via nutrient starvation) are 
required for a robust level of ULK1 activation. 
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